MAPT and Alzheimer disease: Imaging technologies such as PET and MRI and biomarkers in cerebrospinal fluid (CSF) and plasma, specifically amyloid–β (Aβ42) and phosphorylated tau (p-tau), are used to diagnose AD and guide clinical decisions throughout disease progression (Jack, 2024).